参考文献: 1. IgA nephropathy in adults — treatment standard.NDT 2.IgA nephropathy: Treatment and prognosis.UTD 3The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 2013 Jun;24(3):203-15. 4.IgA nephropathy: Pathogenesis.UTD. 5.A Phas...
4. Looking to the Future of IgA Nephropathy Treatment
2.IgA nephropathy: Treatment and prognosis.UTD 3The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 2013 Jun;24(3):203-15. 4.IgA nephropathy: Pathogenesis.UTD. ...
[2]Locatelli F, Del Vecchio L, Ponticelli C. Systemic and targeted steroids for the treatment of IgA nephropathy.Clin Kidney J. 2023;16(Suppl 2):ii40-ii46. Published 2023 Dec 4. doi:10.1093/ckj/sfad224.
1.1126例中国汉族成人IgA肾病患者的长期预后及危险因素分析.肾脏病与透析肾移植杂志.2011. 2.Emerging Modes of Treatment of IgA Nephropathy.Int J Mol Sci 2.60 ERA. Long-term renal benefit over 2 years withNefecon verified: The NefIgArd Phase 3 full trial results....
IgA 肾病(IgA nephropathy, IgAN)是目前世界范围内最常见的原发性肾小球肾病,约占全部肾活检病例的 10%～40%,原发性肾小球疾病的 20%～50%。IgAN 也是我国最常见的肾小球疾病,已成为终末期肾病的重要病因。目前针对 IgA 肾病主要以非靶向支持性疗法为主,包括控制血压和改善蛋白尿,必要时激素联用免疫抑制剂治疗...
美国食品药品监督管理局（FDA）有条件批准布地奈德（budesonide）治疗原发性 IgA 肾病（IgA nephropathy）...
IgA nephropathy (IgAN) is an important cause of progressive kidney disease with 25-30% of patients developing end-stage renal disease within 20 years of diagnosis. There is still no treatment to modify mesangial IgA deposition and available treatments are those extrapolated from the management of ...
3.Gleeson PJ, O'Shaughnessy MM, Barratt J. IgA nephropathy in adults - Treatment Standard. Nephrol Dial Transplant. 2023 Jul 7:gfad146. 4.Li WW, Peng XF, Liu YY, et al. TLR9 and BAFF: Their expression in patients with IgA nephropathy. Mol Med Rep. 2014;10(3):1469–74. ...
2.IgA nephropathy: Treatment and prognosis.UTD 3The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 2013 Jun;24(3):203-15. 4.IgA nephropathy: Pathogenesis.UTD. 5.A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.NEJM...